Abstract

In the paper we presented our allogeneic hematopoietic stem cell transplantation experience in the 15 years period. We presented a new type of transplantation – from match unrelated donors, started in Gdańsk in 2001 year. The indications for the procedure and their changes in the last few years were analysed. In the imatinib era, transplantation is no more the front line therapy in chronic myelogenous leukaemia. The most frequent group of patients had acute leukaemias. We presented different methods of transplantation: the actual bone marrow transplantation, grafting of peripheral blood stem cells and cord blood cells. The second method is the preffered one in our center. We analysed the course of transplantations with particular interest in complications of the procedure. Acute graft versus host disease (aGvHD), a unique complication of hematopoietic stem cell transplantation, was observed in 88% of patients. In 56% of them the clinical course of aGvHD demanded treatment. We also analysed transplant related mortality. The main reason of early mortality was infections – probably due to the dysfunction of pressure of air laminar flow system and transplantation in patient with high transplant risk. In spite of life threatening complications allogeneic hematopoietic stem cell transplantation is the only method that provides cure in over 60% of malignant hematologic diseases.